Danaher Corporation (DHR)

Market Cap	159.81B
Revenue (ttm)	24.27B
Net Income (ttm)	3.50B
Shares Out	706.35M
EPS (ttm)	4.87
PE Ratio	46.49
Forward PE	27.94
Dividend	$1.28 (0.57%)
Ex-Dividend Date	Sep 26, 2025

Volume	3,179,579
Open	228.03
Previous Close	227.13
Day's Range	225.00 - 228.48
52-Week Range	171.00 - 258.23
Beta	0.92
Analysts	Strong Buy
Price Target	246.81 (+9.09%)
Earnings Date	Oct 21, 2025

About DHR

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for man...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1969
• Employees: 63,000
• Stock Exchange: NYSE
• Ticker Symbol: DHR
• Website: https://www.danaher.com

Financial Performance

In 2024, Danaher's revenue was $23.88 billion, a decrease of -0.06% compared to the previous year's $23.89 billion. Earnings were $3.90 billion, a decrease of -17.79%.

Analyst Forecast

According to 17 analysts, the average rating for DHR stock is "Strong Buy." The 12-month stock price target is $246.81, which is an increase of 9.09% from the latest price.

Price Target

$246.81

(9.09% upside)

Analyst Consensus: Strong Buy